CN100389772C - 唑来膦酸盐在生产用于治疗骨代谢疾病的药物中的用途 - Google Patents

唑来膦酸盐在生产用于治疗骨代谢疾病的药物中的用途 Download PDF

Info

Publication number
CN100389772C
CN100389772C CNB018097812A CN01809781A CN100389772C CN 100389772 C CN100389772 C CN 100389772C CN B018097812 A CNB018097812 A CN B018097812A CN 01809781 A CN01809781 A CN 01809781A CN 100389772 C CN100389772 C CN 100389772C
Authority
CN
China
Prior art keywords
zoledronic acid
treatment
bone
minutes
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CNB018097812A
Other languages
English (en)
Chinese (zh)
Other versions
CN1481247A (zh
Inventor
J·J·西曼
B·加利
H·施兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9891987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100389772(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1481247A publication Critical patent/CN1481247A/zh
Application granted granted Critical
Publication of CN100389772C publication Critical patent/CN100389772C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB018097812A 2000-05-19 2001-05-09 唑来膦酸盐在生产用于治疗骨代谢疾病的药物中的用途 Ceased CN100389772C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012209.3A GB0012209D0 (en) 2000-05-19 2000-05-19 Organic compounds
GB0012209.3 2000-05-19

Publications (2)

Publication Number Publication Date
CN1481247A CN1481247A (zh) 2004-03-10
CN100389772C true CN100389772C (zh) 2008-05-28

Family

ID=9891987

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018097812A Ceased CN100389772C (zh) 2000-05-19 2001-05-09 唑来膦酸盐在生产用于治疗骨代谢疾病的药物中的用途

Country Status (9)

Country Link
EP (1) EP1286665B1 (enExample)
JP (3) JP2004501104A (enExample)
CN (1) CN100389772C (enExample)
AU (2) AU2001261283B2 (enExample)
BR (1) BR0110913A (enExample)
CA (1) CA2409930C (enExample)
ES (1) ES2409033T3 (enExample)
GB (1) GB0012209D0 (enExample)
WO (1) WO2001089494A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102000035A (zh) * 2010-10-13 2011-04-06 江苏奥赛康药业有限公司 一种供注射用的唑来膦酸组合物及其制备方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014724A1 (en) 2001-05-09 2004-01-22 Seaman John J. Method of administering a bisphosphonate
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
BR0308901A (pt) 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
TWI344367B (en) * 2002-09-16 2011-07-01 Novartis Ag Use of zoledronic acid or a pharmaceutically acceptable salt or hydrate thereof in the preparation of a medicament for the treatment of osteoporosis post hip fracture
ES2530791T3 (es) 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
WO2006062876A2 (en) 2004-12-09 2006-06-15 Merck & Co., Inc. Estrogen receptor modulators
DK1930414T3 (da) * 2005-09-08 2012-10-22 Medinet Co Ltd Fremgangsmåde til aktiveringsbehandling af antigenpræsenterende celle
JP5829400B2 (ja) * 2008-01-24 2015-12-09 レメドー バイオメッド リミテッド 骨再生のためのエリスロポイエチンおよびフィブロネクチン組成物
DK2473172T3 (en) 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
RU2519120C1 (ru) * 2012-11-06 2014-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
BE1021270B1 (nl) * 2014-06-17 2015-10-14 Neogen N.V. Zoledronine oplossing
CN105213407B (zh) * 2015-07-01 2018-01-02 南京大学 唑来膦酸用于制备治疗脂肪性肝病的药物的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014724A1 (en) 2001-05-09 2004-01-22 Seaman John J. Method of administering a bisphosphonate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clinical research update:zoledronate. BODY J J.CANCER,Vol.80 No.8. 1997
Clinical research update:zoledronate. BODY J J.CANCER,Vol.80 No.8. 1997 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102000035A (zh) * 2010-10-13 2011-04-06 江苏奥赛康药业有限公司 一种供注射用的唑来膦酸组合物及其制备方法

Also Published As

Publication number Publication date
ES2409033T3 (es) 2013-06-24
JP2004501104A (ja) 2004-01-15
JP2012162531A (ja) 2012-08-30
EP1286665B1 (en) 2013-04-17
WO2001089494A2 (en) 2001-11-29
EP1286665A2 (en) 2003-03-05
WO2001089494A8 (en) 2003-04-17
GB0012209D0 (en) 2000-07-12
CA2409930A1 (en) 2001-11-29
WO2001089494A3 (en) 2002-05-23
BR0110913A (pt) 2003-12-30
AU6128301A (en) 2001-12-03
CN1481247A (zh) 2004-03-10
CA2409930C (en) 2012-08-28
AU2001261283B2 (en) 2005-01-13
JP2013151553A (ja) 2013-08-08

Similar Documents

Publication Publication Date Title
JP2012162531A (ja) 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用
AU2002257802B2 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
KR100518391B1 (ko) 비포스포네이트를 함유하는 비경구용 약학 조성물
US20080207565A1 (en) Use of bisphosphonates for pain treatment
AU2001261283A1 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
AU2002257802A1 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
AU2002217061A1 (en) Use of bisphosphonates for pain treatment
JP2010513309A5 (enExample)
JP2004501104A5 (enExample)
Berenson New advances in the biology and treatment of myeloma bone disease
US8324189B2 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
CN1870974B (zh) 注射用加巴喷丁组合物的生产方法
US7169812B2 (en) Process for producing injectable gabapentin compositions
RU2657833C2 (ru) Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и её применение
CN1486696A (zh) 哌仑西平冻干粉针剂
AU2017297989A1 (en) Pharmaceutical preparation for treating bone lesions caused by malignant neoplasms

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

IW01 Full invalidation of patent right
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20161125

Decision number of declaring invalidation: 30563

Granted publication date: 20080528